Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Summary

This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.

Timeline

Start

2022-01-01

Primary completion

2022-12-31

Completion

2023-12-31

Drugs

Indications